Daily Stock Opinions and Ratings

Opinions

Jim Cramer - Mad MoneyEmergent BioSolutions EBSSELLMay 17, 2021

A disaster. He feels bad for J&J that they ever signed a contract with them.

Jim Cramer - Mad Money

Unknown

Unlock Rating

$60.31

Stock price when the opinion was issued

$8.49

As of Jun 01, 2026. Market Open.

biotechnologypharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

COMMENT

EBS is helping to produce Covid vaccines. Despite this, the stock has been hammered 25% from recent high, a victim of the current rotation favouring reopening stocks and dumping other sectors. The stock has gotten too cheap at 10x earnings; it's a growth stock.

BUY

Instead of buying a single vaccine-making pharma, consider this. They have an established vaccine business and are working on plasma-based treatments for Covid. They also have a big contract manufacturing business of vaccines with JNJ, AZN and Novavax. This has fallen $40 from its August peak. But last night they issued bullish future numbers for this year, and the stock jumped 4.7% today. More upside to come.

WATCH

They're involved with JNJ and will mass-produce their Covid vaccine. He expects JNJ will release the next effective vaccine. EBS stock has done nothing because there's no news yet.

Most Recent Experts